Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase Ib, Open-Label, Multicenter Study To Investigate The Pharmacokinetics, Safety, And Tolerability Of Subcutaneous Ocrelizumab Administration In Patients With Multiple Sclerosis

Next Previous
Trial Profile

A Phase Ib, Open-Label, Multicenter Study To Investigate The Pharmacokinetics, Safety, And Tolerability Of Subcutaneous Ocrelizumab Administration In Patients With Multiple Sclerosis

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 16 Jul 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ocrelizumab (Primary) ; Ocrelizumab (Primary) ; Hyaluronidase
  • Indications Multiple sclerosis
  • Focus Adverse reactions; Pharmacokinetics
  • Acronyms Ocarina I
  • Sponsors Roche

Most Recent Events

  • 08 Jul 2025 Status changed from active, no longer recruiting to completed.
  • 18 Apr 2024 Results assessing safety, tolerability and pharmacokinetic data in patients with relapsing and primary progressive multiple sclerosis (RMS/PPMS), to select the appropriate OCR subcutaneous (SC) dose for OCARINA II, were presented at the 76th Annual Meeting of the American Academy of Neurology 2024.
  • 17 Apr 2024 Planned primary completion date changed from 30 Jun 2023 to 20 Jun 2025.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top